DaVita Inc.
Financials
Valuation Metrics
DaVita Inc.'s Market Cap is $14.99B. At end of 2025 it was $9.78B. Ranked #732 of 3,112 in US market (top 24%), #504 of 1,667 on NYSE (top 30%), #46 of 206 in Health Care Equipment & Services (top 22%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $14.99B | US#732/3,112 Sec#46/206 |
| Revenue | $13.84B | US#454/3,112 Sec#28/206 |
| Net Income | $781M | US#624/3,112 Sec#39/206 |
| Total Assets | $17.50B | US#668/3,112 Sec#31/206 |
| Net Assets | $387M | US#2,426/3,112 Sec#132/206 |
| Employees | 78,000 | US#102/3,112 Sec#10/206 |
| Value | ||
| P/E | 19.19x | US#976/3,112 Sec#21/206 |
| P/B | 38.77x | US#2,907/3,112 Sec#198/206 |
| PEG | 0.90x | US#794/3,112 Sec#32/206 |
| P/S | 1.08x | US#715/3,112 Sec#48/206 |
| EV/EBITDA | 10.18x | US#786/3,112 Sec#25/206 |
| FCF Yield | 9.96% | US#512/3,112 Sec#19/206 |
| Profitability | ||
| ROA | 4.47% | US#1,097/3,112 Sec#67/206 |
| Op. Margin | 15.01% | US#1,229/3,112 Sec#47/206 |
| Revenue Growth | 5.96% | US#1,656/3,112 Sec#124/206 |
| Earnings Growth | 21.25% | US#897/3,112 Sec#42/206 |
| Financial Health | ||
| Debt Ratio | 4254.09% | US#2,977/3,112 Sec#202/206 |
| Total Debt | $13.22B | US#331/3,112 Sec#16/206 |
| FCF | $1.49B | US#440/3,112 Sec#28/206 |
| Cash | $726M | US#854/3,112 Sec#46/206 |
| Current Ratio | 1.42x | US#1,757/3,112 Sec#158/206 |
| Net Debt/EBITDA | 4.63x | US#1,990/3,112 Sec#126/206 |
| Performance | ||
| 1Y Return | 68.69% | US#516/3,112 Sec#44/206 |
| 1M Return | -0.56% | US#1,732/3,112 Sec#116/206 |
| From 52W High | -5.61% | US#618/3,112 Sec#43/206 |
| 1Y MDD | -31.36% | US#1,480/3,112 Sec#61/206 |
| Trading | ||
| Volume | 1,195,380 shares | US#1,331/3,112 Sec#86/206 |
| Trading Value | $284M | US#379/3,112 Sec#30/206 |
| Per Share | ||
| EPS | $8.67 | US#310/3,112 Sec#23/206 |
Company Info
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.